CTXR vs. REGN

Last updated Apr 2, 2026

Compare and contrast key facts about Citius Pharmaceuticals, Inc. (CTXR) and Regeneron Pharmaceuticals, Inc. (REGN).

Performance

CTXR vs. REGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Citius Pharmaceuticals, Inc. (CTXR) and Regeneron Pharmaceuticals, Inc. (REGN). The values are adjusted to include any dividend payments, if applicable.

CTXR vs. REGN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CTXR Citius Pharmaceuticals, Inc.	8.51%	-80.57%	-78.85%	-4.24%	-48.70%	50.98%	-0.00%	-1.92%	-72.63%	-37.70%
REGN Regeneron Pharmaceuticals, Inc.	0.82%	8.96%	-18.90%	21.73%	14.25%	30.72%	28.66%	0.53%	-0.65%	-23.30%

Fundamentals

Market Cap CTXR : $18.12M REGN : $83.55B
EPS CTXR : -$2.20 REGN : $41.80
PS Ratio CTXR : 3.60 REGN : 5.84
PB Ratio CTXR : 0.23 REGN : 2.21
Total Revenue (TTM) CTXR : $3.94M REGN : $14.34B
Gross Profit (TTM) CTXR : $3.00M REGN : $12.54B
EBITDA (TTM) CTXR : -$36.47M REGN : $5.50B

Returns By Period

In the year-to-date period, CTXR achieves a 8.51% return, which is significantly higher than REGN's 0.82% return.

CTXR

• 1D: -6.32%
• 1M: 16.61%
• YTD: 8.51%
• 6M: -38.46%
• 1Y: -29.74%
• 3Y*: -69.34%
• 5Y*: -55.06%
• 10Y*: —

REGN

• 1D: 0.60%
• 1M: -1.71%
• YTD: 0.82%
• 6M: 29.87%
• 1Y: 26.66%
• 3Y*: -1.61%
• 5Y*: 10.50%
• 10Y*: 6.80%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CTXR vs. REGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CTXR

CTXR Risk / Return Rank: 31
CTXR Sharpe Ratio Rank: 30
CTXR Sortino Ratio Rank: 43
CTXR Omega Ratio Rank: 40
CTXR Calmar Ratio Rank: 19
CTXR Martin Ratio Rank: 23

REGN

REGN Risk / Return Rank: 62
REGN Sharpe Ratio Rank: 64
REGN Sortino Ratio Rank: 57
REGN Omega Ratio Rank: 59
REGN Calmar Ratio Rank: 63
REGN Martin Ratio Rank: 65

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CTXR vs. REGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Citius Pharmaceuticals, Inc. (CTXR) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CTXR	REGN	Difference
Sharpe ratio Return per unit of total volatility	-0.23	0.66	-0.89
Sortino ratio Return per unit of downside risk	0.58	1.09	-0.51
Omega ratio Gain probability vs. loss probability	1.06	1.16	-0.10
Calmar ratio Return relative to maximum drawdown	-0.62	1.02	-1.65
Martin ratio Return relative to average drawdown	-0.95	2.62	-3.57
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CTXR vs. REGN - Sharpe Ratio Comparison

The current CTXR Sharpe Ratio is -0.23, which is lower than the REGN Sharpe Ratio of 0.66. The chart below compares the historical Sharpe Ratios of CTXR and REGN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CTXR	REGN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.23	0.66	-0.89
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.59	0.35	-0.94
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.21	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.47	0.17	-0.64

Correlation

The correlation between CTXR and REGN is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CTXR vs. REGN - Dividend Comparison

CTXR has not paid dividends to shareholders, while REGN's dividend yield for the trailing twelve months is around 0.46%.

	TTM	2025
CTXR Citius Pharmaceuticals, Inc.	0.00%	0.00%
REGN Regeneron Pharmaceuticals, Inc.	0.46%	0.46%

Drawdowns

CTXR vs. REGN - Drawdown Comparison

The maximum CTXR drawdown since its inception was -99.57%, which is greater than REGN's maximum drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for CTXR and REGN.

Drawdown Indicators

	CTXR	REGN	Difference
Max Drawdown Largest peak-to-trough decline	-99.57%	-91.81%	-7.76%
Max Drawdown (1Y) Largest decline over 1 year	-69.89%	-22.67%	-47.22%
Max Drawdown (5Y) Largest decline over 5 years	-99.37%	-59.69%	-39.68%
Max Drawdown (10Y) Largest decline over 10 years	—	-59.69%	—
Current Drawdown Current decline from peak	-99.46%	-34.89%	-64.57%
Average Drawdown Average peak-to-trough decline	-79.51%	-42.39%	-37.12%
Ulcer Index Depth and duration of drawdowns from previous peaks	45.80%	8.86%	+36.94%

Volatility

CTXR vs. REGN - Volatility Comparison

Citius Pharmaceuticals, Inc. (CTXR) has a higher volatility of 43.73% compared to Regeneron Pharmaceuticals, Inc. (REGN) at 8.45%. This indicates that CTXR's price experiences larger fluctuations and is considered to be riskier than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CTXR	REGN	Difference
Volatility (1M) Calculated over the trailing 1-month period	43.73%	8.45%	+35.28%
Volatility (6M) Calculated over the trailing 6-month period	81.30%	23.88%	+57.42%
Volatility (1Y) Calculated over the trailing 1-year period	131.74%	40.58%	+91.16%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.82%	30.27%	+63.55%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	95.64%	32.21%	+63.43%

Financials